Paper29856472
Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
Chen M and 11 others. Aliment Pharmacol Ther, 2018. Cited by 51 papers, by iCite.
Cite this record
ConductScience Library. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome. Papers, record 29856472. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29856472
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diarrhea | Major topic |
| Drugs, Chinese Herbal | Major topic |
| Irritable Bowel Syndrome | Major topic |
| Abdominal Pain | |
| Administration, Oral | |
| Adult | |
| Dosage Forms | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Placebos | |
| Treatment Outcome | |
| Young Adult |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02538692 | Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 30588695 | Editorial: Tong-Xie-Yao-Fang (TXYF) for irritable bowel syndrome with diarrhoea (IBS-D)-ancient medicine meets modern study. | https://conductscience.org/library/papers/30588695 | PubMed |
| Comment in | 30588696 | Editorial: Tong-Xie-Yao-Fang (TXYF) for irritable bowel syndrome with diarrhoea (IBS-D)-ancient medicine meets modern study. Authors' reply. | https://conductscience.org/library/papers/30588696 | PubMed |
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979303 | Xifenghuashi formula ameliorates diarrhea predominant-irritable bowel syndrome by modulating the gut microbiota and the bile acid-FXR-FGF axis: A human trial and an animal experiment. | J Tradit Complement Med | 2026 | https://conductscience.org/library/papers/42979303 | PubMed |
| 42572206 | Systematic Review and Meta-Analysis: Plant-Based Therapy for Irritable Bowel Syndrome. | Phytother Res | 2026 | https://conductscience.org/library/papers/42572206 | PubMed |
| 41641200 | Clinical efficacy of Xifeng Huashi and its effect on mental status in patients with diarrheal irritable bowel. | World J Psychiatry | 2026 | https://conductscience.org/library/papers/41641200 | PubMed |
| 41599795 | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. | Nutrients | 2026 | https://conductscience.org/library/papers/41599795 | PubMed |
| 41096612 | Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41096612 | PubMed |
| 41034986 | Changji'an formula alleviates visceral hypersensitivity of a post-inflammatory IBS-D mouse model via NGF/TrkA signaling pathway. | BMC Complement Med Ther | 2025 | https://conductscience.org/library/papers/41034986 | PubMed |
| 39998756 | Placebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis. | Qual Life Res | 2025 | https://conductscience.org/library/papers/39998756 | PubMed |
| 39870499 | Chinese herbal formula Tongxie Yaofang granules for diarrhoea-predominant irritable bowel syndrome: a randomised, double-blind, placebo-controlled, phase II trial. | BMJ Open | 2025 | https://conductscience.org/library/papers/39870499 | PubMed |
| 39669195 | Herbal placebo response in clinical trials on irritable bowel syndrome: a systematic review and meta-analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39669195 | PubMed |
| 39355776 | Traditional Chinese medicine for functional gastrointestinal disorders and inflammatory bowel disease: narrative review of the evidence and potential mechanisms involving the brain-gut axis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39355776 | PubMed |
| 39143474 | How fragile the positive results of Chinese herbal medicine randomized controlled trials on irritable bowel syndrome are? | BMC Complement Med Ther | 2024 | https://conductscience.org/library/papers/39143474 | PubMed |
| 39081703 | Tongxieyaofang Decotion Alleviates IBS by Modulating CHRM3 and Gut Barrier. | Drug Des Devel Ther | 2024 | https://conductscience.org/library/papers/39081703 | PubMed |
| 38186470 | Atractylodes macrocephala-Paeonia lactiflora Class Formula for the Treatment of Irritable Bowel Syndrome: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. | Cureus | 2023 | https://conductscience.org/library/papers/38186470 | PubMed |
| 37397480 | Utilization patterns and prescription characteristics of traditional Chinese medicine among patients with irritable bowel syndrome in Taiwan. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37397480 | PubMed |
| 36590561 | Paeoniflorin alleviates inflammatory response in IBS-D mouse model via downregulation of the NLRP3 inflammasome pathway with involvement of miR-29a. | Heliyon | 2022 | https://conductscience.org/library/papers/36590561 | PubMed |
| 36376576 | Current and Future Therapeutic Options for Irritable Bowel Syndrome with Diarrhea and Functional Diarrhea. | Dig Dis Sci | 2023 | https://conductscience.org/library/papers/36376576 | PubMed |
| 36091782 | Systematic review and meta-analysis of Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: Evidence for clinical practice and future trials. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36091782 | PubMed |
| 35966738 | Effect and Mechanism of Flavored Tongxie Yaofang Decoction for Diarrheal Irritable Bowel Syndrome under Intestinal Microecology. | Evid Based Complement Alternat Med | 2022 | https://conductscience.org/library/papers/35966738 | PubMed |
| 35645323 | An Asian perspective on irritable bowel syndrome. | Intest Res | 2023 | https://conductscience.org/library/papers/35645323 | PubMed |
| 35635135 | Herbal Formula Shenling Baizhu San for Chronic Diarrhea in Adults: A Systematic Review and Meta-analysis. | Integr Cancer Ther | 2022 | https://conductscience.org/library/papers/35635135 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29856472
GET https://conductscience.org/api/papers/v1/29856472/cited_by?page=2